Welcome to our dedicated page for Coeptis Therapeutics SEC filings (Ticker: COEP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Coeptis Therapeutics Holdings Inc. filings document the issuer’s completed merger-related corporate transition, including the name change to Z Squared Inc. and the surviving operating subsidiary Z Squared OpCo Inc. The record includes Form 8-K material-event reports covering capital-structure changes, governance matters, shareholder voting matters, material agreements, operating and financial results, and clinical or regulatory disclosures connected to Coeptis's biotechnology operations.
Additional filings document security-status and compensation matters, including a Form 25 for removal of warrants from Nasdaq listing and registration and an option repricing and exchange program under the 2022 Equity Incentive Plan. The disclosures also cover capital-structure instruments associated with material agreements.
Coeptis Therapeutics Holdings, Inc. director Tara DeSilva reported acquiring additional common stock on February 11, 2026. She obtained 5,700 shares through the exercise of stock options at an exercise price of $10.56 per share, and separately received a grant of 3,250 restricted shares in connection with an option exchange program where underwater options were surrendered. Following these transactions, she directly holds 8,950 shares of Coeptis Therapeutics common stock.
Coeptis Therapeutics Holdings, Inc. officer Christine Elise Sheehy, VP Compliance and Secretary, increased her direct holdings of common stock through compensation-related transactions. On February 11, 2026, she exercised stock options to acquire 1,000 shares of common stock at an exercise price of $10.56 per share, reflecting the cost to convert her options into shares.
On the same date, she also acquired 12,500 shares of restricted common stock at $0 per share as part of an option exchange program in which underwater options were surrendered for restricted stock. After these transactions, she directly beneficially owned 64,031 shares of Coeptis common stock.
Coeptis Therapeutics Holdings, Inc. implemented a one-time option repricing and exchange program for options under its 2022 Equity Incentive Plan, covering officers and directors. Holders could either reprice underwater options or surrender them for restricted stock, and all options were made fully vested.
Several executives, including CEO David Mehalick, exchanged underwater options for an equal number of restricted shares and exercised remaining vested options to receive restricted common stock. The company also received notice from Nasdaq that it has regained compliance with the annual meeting requirement, so its Nasdaq Capital Market listing is no longer at risk from that issue.
Coeptis Therapeutics Holdings, Inc. reported the results of its Annual and Special Meeting of Stockholders held on January 30, 2026. Stockholders considered nine proposals described in the company’s proxy statement.
A quorum was present, with 3,697,558 shares represented out of 5,680,111 shares of common stock outstanding as of the January 2, 2026 record date. Multiple proposals received strong support, with several “FOR” vote totals above 3.45 million shares versus materially smaller “AGAINST” and abstention counts.
Stockholders also voted on the election of five directors. Bryan Fuerst, Adam Sohn, David Halabu, Michelle Burke, and Kenneth Cooper each received approximately 3.69 million “FOR” votes, with very few votes withheld and no broker non-votes reported. An adjournment proposal related to Proposals 1–8 was listed as Proposal 9 but was not presented at the meeting.
The Vanguard Group has disclosed a significant ownership position in Coeptis Therapeutics Holdings Inc common stock. Vanguard reports beneficial ownership of 339,486 shares, representing 6.35% of the outstanding common stock, with shared voting power over 26,244 shares and shared dispositive power over 339,486 shares.
The Vanguard Total Stock Market Index Fund Investor Shares is separately reported as beneficially owning 268,093 shares, or 5.02% of the class, with sole voting power over those shares. Vanguard notes an internal realignment effective January 12, 2026, after which certain subsidiaries will report beneficial ownership on a disaggregated basis. The filing certifies that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Coeptis.
Coeptis Therapeutics Holdings, Inc. has issued a prospectus supplement to correct the “Principal Stockholders of Proposed Combined Company” table in its S-4 proxy statement/prospectus for the planned merger.
The supplement assumes that the merger consideration will equal approximately 79% of the combined company’s issued and outstanding common stock at closing, based on 5,762,221 Coeptis shares outstanding on the date of the supplement. Under these assumptions, BSG Series LLC is shown as beneficially owning 22,459,490 shares, or 73.37%, immediately after the merger, with executive officers and directors as a group at 854,775 shares, or 2.79%. BSG Series LLC is expected to distribute its merger shares pro rata to its members in a “BSG Dividend,” after which no single BSG member will beneficially own more than 5% of Coeptis common stock.
Coeptis Therapeutics Holdings, Inc. reported that it received a notice from the Nasdaq Capital Market stating it is not in compliance with Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G). The issue stems from not holding an annual meeting of shareholders within twelve months of its fiscal year ended December 31, 2024.
Nasdaq has given the company 45 calendar days from January 12, 2026 to submit a plan to regain compliance and may grant an exception of up to 180 days from the fiscal year end, through June 29, 2026. The company has already scheduled an annual meeting of shareholders for January 30, 2026 and believes this meeting will be sufficient to regain compliance with the annual meeting requirement.
Coeptis Therapeutics Holdings, Inc. filed a prospectus supplement covering the resale, from time to time, by selling stockholders of up to 3,919,349 shares of common stock. This total includes 100,000 shares held by selling stockholders, up to 3,737,472 shares tied to the Yorkville SEPA (including 20,000 commitment shares and up to 3,717,472 issuable), and 81,877 shares issued upon partial note conversion.
The supplement attaches the company’s Q3 2025 report. For the quarter ended September 30, 2025, sales were $237,441 with a net loss of $2,898,763; year-to-date net loss was $10,654,290. Cash was $4,908,487 as of September 30, 2025. Financing activities provided $11,290,728 year-to-date, including 165,000 SEPA shares for $2,039,195 and a private placement of 436,467 shares for $5,000,000. The company disclosed that these conditions raise substantial doubt about its ability to continue as a going concern. Shares outstanding were 5,340,111 as of November 11, 2025; this is a baseline figure, not the amount being offered.
Coeptis Therapeutics Holdings, Inc. filed Prospectus Supplement No. 9 to its November 29, 2023 prospectus, covering the resale of up to 12,080,000 shares of common stock by selling stockholders. The supplement also attaches the company’s Form 10‑Q for the quarter ended September 30, 2025.
The registered resale shares consist of:
- 6,527,000 currently issued shares
- 1,223,000 shares issuable upon exercise of pre‑funded warrants
- 2,000,000 shares issuable upon exercise of Series A Warrants
- 2,000,000 shares issuable upon exercise of Series B Warrants
- 210,000 shares issuable upon exercise of underwriter warrants from the June 2023 offering
- 120,000 shares issuable upon exercise of placement agent warrants from the October 2023 private placement
The company states the registration is to satisfy registration rights granted to selling stockholders. As context, shares outstanding were 5,340,111 as of November 11, 2025. The common stock trades on Nasdaq under “COEP,” and the reported closing price was $14.15 on November 13, 2025.
Coeptis Therapeutics Holdings (COEP) filed its Q3 2025 report, showing the first meaningful revenue from its technology segment. Sales were $237,441 in the quarter and $500,996 year-to-date, producing Q3 gross profit of $192,286.
Costs remained heavy as the company builds its biopharma and tech platforms: Q3 operating expenses were $2.67M, leading to a loss from operations of $2.48M and a net loss of $2.90M (nine‑month net loss $10.65M). Cash improved to $4.91M at September 30, 2025, up from $0.53M at year‑end, driven by financing inflows of $11.29M year‑to‑date (including a Q3 private placement of 436,467 shares for $5.0M). Operating cash use was $6.92M year‑to‑date.
The company reported $1.46M in customer deposits and completed the exclusive GEAR cell therapy license, paying $400,000 in 2025 with future milestones. Equity activity was significant: common shares outstanding rose to 5,157,611 at September 30, 2025, and 5,340,111 as of November 11, 2025. Management disclosed that recurring losses and an accumulated deficit of $108.38M raise substantial doubt about continuing as a going concern, with plans to seek additional financing.